Endocrine News and Research

RSS
BioSante announces presentation of LibiGel safety update at ENDO 2010

BioSante announces presentation of LibiGel safety update at ENDO 2010

VIVUS to present data on Qnexa at ENDO meeting

VIVUS to present data on Qnexa at ENDO meeting

Prevention, awareness of enlarged prostate can help save lives

Prevention, awareness of enlarged prostate can help save lives

Molecular imaging fusion with CT anatomy results in precise localization of parathyroid lesions: Research

Molecular imaging fusion with CT anatomy results in precise localization of parathyroid lesions: Research

Many Huntington's disease patients suffer from weight loss, sleeping problems

Many Huntington's disease patients suffer from weight loss, sleeping problems

Aeterna Zentaris to present poster on AEZS-130 growth hormone secretagogue/ghrelin receptor agonist at 92nd ENDO

Aeterna Zentaris to present poster on AEZS-130 growth hormone secretagogue/ghrelin receptor agonist at 92nd ENDO

Biodel announces schedule for presentations at 70th Scientific Sessions of American Diabetes Association

Biodel announces schedule for presentations at 70th Scientific Sessions of American Diabetes Association

New guideline to improve IHC testing for expression status of ER and PgR in breast cancer issued

New guideline to improve IHC testing for expression status of ER and PgR in breast cancer issued

Chiasma successfully completes Phase I clinical study of Octreolin

Chiasma successfully completes Phase I clinical study of Octreolin

Aeterna Zentaris reports final results on clinical activity of perifosine for metastatic colorectal cancer

Aeterna Zentaris reports final results on clinical activity of perifosine for metastatic colorectal cancer

Aeterna Zentaris presents data of perifosine Phase 1 trial for recurrent pediatric solid tumors at ASCO

Aeterna Zentaris presents data of perifosine Phase 1 trial for recurrent pediatric solid tumors at ASCO

Aeterna Zentaris presents positive data from AEZS-108 Phase 2 study in ovarian cancer at ASCO 2010

Aeterna Zentaris presents positive data from AEZS-108 Phase 2 study in ovarian cancer at ASCO 2010

Bisphosphonates may cause poorer survival rate in women with early stage breast cancer: Study

Bisphosphonates may cause poorer survival rate in women with early stage breast cancer: Study

Positive results from Phase 3 trial of ipilimumab in patients with metastatic melanoma

Positive results from Phase 3 trial of ipilimumab in patients with metastatic melanoma

Chemotherapy-induced amenorrhea improves survival in premenopausal women with early stage breast cancer

Chemotherapy-induced amenorrhea improves survival in premenopausal women with early stage breast cancer

Brain's cardiovascular, hormonal and asymmetric activation response when we get angry: UV scientists

Brain's cardiovascular, hormonal and asymmetric activation response when we get angry: UV scientists

Exposure in womb to BPA, DES increase offspring's risk of breast cancer

Exposure in womb to BPA, DES increase offspring's risk of breast cancer

Aggressive treatment of anaplastic thyroid carcinoma increases survival: Study

Aggressive treatment of anaplastic thyroid carcinoma increases survival: Study

Women with recurrent miscarriages can have successful pregnancy with supportive care

Women with recurrent miscarriages can have successful pregnancy with supportive care

Study measures effects of BPA on male reproductive system

Study measures effects of BPA on male reproductive system

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.